Vigilant Capital Management LLC raised its position in Novartis AG (NYSE:NVS) by 950.9% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,219 shares of the company’s stock after purchasing an additional 1,103 shares during the period. Vigilant Capital Management LLC’s holdings in Novartis were worth $106,000 as of its most recent filing with the Securities and Exchange Commission.
Several other large investors have also recently made changes to their positions in the business. Fisher Asset Management LLC increased its position in shares of Novartis by 3.4% in the 2nd quarter. Fisher Asset Management LLC now owns 8,827,829 shares of the company’s stock valued at $771,023,000 after purchasing an additional 292,961 shares during the last quarter. Morgan Stanley boosted its holdings in shares of Novartis by 34.6% in the 1st quarter. Morgan Stanley now owns 3,755,914 shares of the company’s stock valued at $309,675,000 after buying an additional 965,770 shares in the last quarter. The Manufacturers Life Insurance Company boosted its holdings in shares of Novartis by 2.2% in the 1st quarter. The Manufacturers Life Insurance Company now owns 3,223,763 shares of the company’s stock valued at $265,800,000 after buying an additional 69,706 shares in the last quarter. Neuberger Berman Group LLC boosted its holdings in shares of Novartis by 20.9% in the 2nd quarter. Neuberger Berman Group LLC now owns 2,492,252 shares of the company’s stock valued at $217,686,000 after buying an additional 431,326 shares in the last quarter. Finally, Clearbridge Investments LLC boosted its holdings in shares of Novartis by 8.2% in the 1st quarter. Clearbridge Investments LLC now owns 1,879,774 shares of the company’s stock valued at $154,987,000 after buying an additional 142,047 shares in the last quarter. 10.37% of the stock is currently owned by institutional investors.
Several brokerages have recently issued reports on NVS. UBS Group upgraded shares of Novartis from a “neutral” rating to a “buy” rating in a report on Thursday, September 10th. Oddo Bhf cut shares of Novartis from a “buy” rating to a “neutral” rating in a research note on Wednesday, September 23rd. Morgan Stanley upgraded shares of Novartis from an “equal weight” rating to an “overweight” rating in a research report on Tuesday, September 1st. JPMorgan Chase & Co. restated an “underweight” rating on shares of Novartis in a research report on Wednesday, August 12th. Finally, Berenberg Bank started coverage on shares of Novartis in a report on Tuesday, September 29th. They issued a “buy” rating for the company. Three research analysts have rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $108.00.
Novartis stock opened at $86.19 on Friday. Novartis AG has a 12-month low of $69.18 and a 12-month high of $99.84. The stock has a market capitalization of $197.26 billion, a P/E ratio of 27.45, a P/E/G ratio of 1.90 and a beta of 0.42. The firm’s 50-day moving average is $87.88 and its two-hundred day moving average is $86.37. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.81 and a quick ratio of 0.58.
Novartis (NYSE:NVS) last released its quarterly earnings results on Tuesday, July 21st. The company reported $1.36 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.31 by $0.05. Novartis had a net margin of 14.96% and a return on equity of 24.14%. The company had revenue of $11.35 billion for the quarter, compared to analysts’ expectations of $11.77 billion. During the same period last year, the company earned $1.34 EPS. The firm’s revenue for the quarter was down 3.5% compared to the same quarter last year. As a group, analysts forecast that Novartis AG will post 5.73 EPS for the current year.
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. Its Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, established, and cardiovascular, renal and metabolism medicine products.
Further Reading: What is a CD ladder?
Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.